Physician profile
Aamer Farooq
NPI 1518165919
$17,161.02
in general payments reported to CMS, 2019-2025
68 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $373 · 2021: $361 · 2022: $1,819 · 2023: $3,079 · 2024: $10K · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,809 · Consulting Fee: $3,981 · Food and Beverage: $3,838 · Travel and Lodging: $1,411 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,809.36 |
| Consulting Fee | $3,981.00 |
| Food and Beverage | $3,837.78 |
| Travel and Lodging | $1,411.22 |
| Education | $105.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $5,791.44 | 2023-2024 | Optune Lua (Novottf-200t) |
| Astellas Pharma US INC | $4,868.32 | 2020-2025 | Xospata, Padcev |
| Novartis Pharmaceuticals Corporation | $607.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $379.91 | 2022-2025 | Enhertu, Tagrisso, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $378.94 | 2019-2023 | Reblozyl, Opdivo |
| Karyopharm Therapeutics INC. | $363.57 | 2020-2025 | Xpovio |
| Seagen INC. | $321.21 | 2021-2023 | Adcetris |
| Incyte Corporation | $282.00 | 2020-2025 | Jakafi |
| Merck Sharp & Dohme LLC | $279.46 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $251.22 | 2019-2025 | Darzalex, Talvey, Imbruvica |
| Sobi, INC | $237.21 | 2022-2024 | |
| Pfizer INC. | $225.02 | 2022-2025 | |
| Genentech USA, INC. | $212.01 | 2022-2023 | Lunsumio, Tecentriq, Polivy |
| Foundation Medicine, INC. | $207.62 | 2019-2020 | |
| Celgene Corporation | $159.28 | 2021-2025 | Opdualag, Reblozyl, Pomalyst |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aamer Farooq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.